Prudential Financial Inc. Sells 10,529 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Prudential Financial Inc. cut its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 15.1% in the 4th quarter, HoldingsChannel.com reports. The fund owned 59,034 shares of the biopharmaceutical company’s stock after selling 10,529 shares during the period. Prudential Financial Inc.’s holdings in Regeneron Pharmaceuticals were worth $42,052,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently modified their holdings of the company. Dillon & Associates Inc. grew its stake in Regeneron Pharmaceuticals by 2.8% in the 4th quarter. Dillon & Associates Inc. now owns 13,899 shares of the biopharmaceutical company’s stock valued at $9,896,000 after purchasing an additional 374 shares during the period. Crowley Wealth Management Inc. bought a new position in Regeneron Pharmaceuticals during the fourth quarter valued at about $36,000. KLP Kapitalforvaltning AS purchased a new stake in Regeneron Pharmaceuticals during the fourth quarter worth about $34,468,000. Umpqua Bank raised its position in Regeneron Pharmaceuticals by 7.6% in the fourth quarter. Umpqua Bank now owns 1,534 shares of the biopharmaceutical company’s stock worth $1,060,000 after acquiring an additional 108 shares during the period. Finally, Forefront Wealth Management Inc. purchased a new position in Regeneron Pharmaceuticals in the fourth quarter valued at about $2,206,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently commented on REGN shares. BMO Capital Markets lowered their price target on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a report on Tuesday, February 4th. Canaccord Genuity Group initiated coverage on Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target for the company. Leerink Partners upgraded Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their price objective for the company from $762.00 to $834.00 in a research note on Wednesday, February 5th. Bernstein Bank reduced their target price on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. Finally, Wells Fargo & Company dropped their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a research note on Friday, January 10th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $634.14 on Wednesday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $633.10 and a fifty-two week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The stock has a market cap of $69.33 billion, a P/E ratio of 16.57, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27. The firm’s fifty day moving average price is $687.18 and its 200-day moving average price is $806.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter last year, the business posted $11.86 earnings per share. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. On average, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.56%. The ex-dividend date of this dividend was Thursday, February 20th. Regeneron Pharmaceuticals’s payout ratio is currently 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.